The actual cost of palbociclib/palbociclib after medical insurance reimbursement

Palbociclib/Pabociclib, an oral targeted therapy for breast cancer approved by the U.S. Food and Drug Administration (FDA), has been launched in my country and included in the medical insurance system, providing financial support to patients with specific indications. This drug is a CDK4/6 inhibitor that can effectively inhibit the proliferation and growth of breast cancer cells. It is often used in combination with other drugs such as steroid estrogen receptor modulators (SERD) or aromatase inhibitors (AI) to enhance the efficacy.

In the Chinese market, the main specifications of palbociclib include 75 mg 21 tablets, 100 mg 21 tablets and 125 mg 21 tablets. Its original price remains at about RMB 5,000. However, due to the implementation of medical insurance policies, eligible patients only need to bear part of the cost after reimbursement. Specific post-reimbursement prices vary by region, so the actual amount paid will vary.

In contrast, the price of the overseas version of the original drug is significantly higher. Taking the specification of 125 mg and 21 capsules as an example, the price may be as high as about 10,000 yuan (the price may fluctuate due to exchange rate effects). At the same time, generic drugs also exist in overseas markets. Although the manufacturers are different, the main ingredients of the drugs are the same as the original drugs, but the prices are significantly lower. For example, the price of a generic drug of the same specification produced by a Bangladeshi pharmaceutical factory is only about 900 yuan. Of course, this price will also fluctuate with changes in the exchange rate.

In general, the medical insurance reimbursement policy for palbociclib/palbociclib has reduced the financial burden on patients and made this important treatment more accessible. However, patients still need to understand the specific reimbursement ratio and actual payment amount based on their own situation and the medical insurance policy in their region.